CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Part of paid clinical trials in Boston, Massachusetts.

Sponsor
Marcela V. Maus, M.D.,Ph.D.
Study ID
NCT06026319
Phase
PHASE1
Status
Recruiting
Apply to this trial

Conditions

  • Diffuse Large B Cell Lymphoma
  • Follicular Lymphoma
  • Grade 3b Follicular Lymphoma
  • High-grade B-cell Lymphoma
  • Mantle Cell Lymphoma
  • Marginal Zone Lymphoma
  • Non-hodgkin Lymphoma
  • Primary Mediastinal Large B-cell Lymphoma (PMBCL)
  • Refractory Non-Hodgkin Lymphoma
  • Relapsed Non-Hodgkin Lymphoma

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • CD79b-19 CAR T cells — DRUG
    Intravenous infusion
  • Cyclophosphamide — DRUG
    Intravenous infusion
  • Fludarabine — DRUG
    Intravenous infusion

Study Details

This research study involves the study of CD79b-19 CAR T cells for treating people with relapsed/refractory Non-Hodgkin Lymphoma and to understand the side effects when treated with CD79b-19 CAR T cells. This research study involves the study drugs: * CD79b-19 CAR T cells * Fludarabine and Cyclophosphamide: Standardly used chemotherapy drugs as part of lymphodepleting process

Key Dates

Start date
Oct 26, 2023
Status verified
Mar 2026
Primary completion
Jan 1, 2027
Completion
Jan 1, 2028

Study Design

Enrollment
24 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: CD79b-19 CAR T cells
    Prior to receiving CD79b-19 CAR T cells, participants will undergo two preparatory processes: * Leukapheresis: During Week -3 white blood cells will be collected. * Lymphodepletion: On days, -5 to -3 participants will receive 3 days of chemotherapy to decrease the number of lymphocytes CD79b-19 CAR T cells will be administered intravenously on day 0 only. The dose you will receive will depend on the number of participants who have been enrolled prior and how well the dose was tolerated. The CD79b-19 CAR T cells will be administered over approximately 1 hour.

Primary Outcome Measure

Incidence of adverse events (AEs) [ Time Frame: From Day 0 to 2 years post-treatment ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Massachusetts General HospitalBostonMassachusetts02114
Matthew Frigault, MD
[email protected]
(617) 643-6175
Matthew Frigault, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Boston, MA

By research site
Massachusetts General Hospital· Boston, MA

Related Studies